Fábio Pires de Souza Santos

Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

Elsa Bernard, Heinz Tuechler, Peter L. Greenberg et al. · NEJM Evidence · 2022 · 813 citations · Full text

Medicine, Genetics, Hematology +16

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Elsa Bernard, Yasuhito Nannya, Robert P. Hasserjian et al. · Nature Medicine · 2020 · 636 citations · Full text

Life Sciences, Genetics, Molecular Genetics +14

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

Fábio Pires de Souza Santos, Hagop M. Kantarjian, Nitin Jain et al. · Blood · 2009 · 234 citations · Full text

Medicine, Hematology, Pharmacology +6

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib

Keyur P. Patel, Kate J. Newberry, Rajyalakshmi Luthra et al. · Blood · 2015 · 188 citations · Full text

Medicine, Genetics, Pharmacology +11

Prognostic impact of RAS-pathway mutations in patients with myelofibrosis

Fábio Pires de Souza Santos, Bartlomiej Getta, Lucia Masárová et al. · Leukemia · 2019 · 82 citations · Full text

Medicine, Hematology, Oncology +14